SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 100 mcg/0.5mL dose or 50 mcg/0.25mL doseĬOVID-19, mRNA, LNP-S, PF, 100 mcg/0.5mL dose or 50 mcg/0.25mL dose Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease ) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5×1010 viral particles/0.5 mL dosage, for intramuscular useįDA EUA update of rescinds use of this monovalent vaccine.ġ00 mcg/0.5 mL for adult primary series and IC dose 12+ (existing product) SARS-COV-2 (COVID-19) vaccine, vector non-replicating, recombinant spike protein-Ad26, preservative free, 0.5 mLĬOVID-19 vaccine, vector-nr, rS-Ad26, PF, 0.5 mL Manufacturerĥ×10^10 viral particles/0.5 mL for adult 18+ You can access further information regarding the COVID-19 CPT codes, as well as the associated coding guidance, using the following link:ĭownload the Preview Table for US vaccine administration only: Excel VersionĬOVID-19 vaccine codes and crosswalks are provided in anticipation of potential vaccine availability under an approved Biologics License Application (BLA), Emergency Use Authorization (EUA), or as a potential vaccine submission for EUA (Pre-EUA). The CPT vaccine product codes are included in the Preview COVID-19 table and the CDC vaccine code sets. Additional code details and fields values are included in the vaccine code sets.Īmerican Medical Association (AMA) COVID-19 CPT® vaccine product and administration codes are now available on the AMA web site. The codes for these vaccines are also included in the vaccine code set files unless otherwise noted in the table.
To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance. The following downloadable table provides a summary of the currently authorized vaccine codes and a preview of the vaccine codes that will be activated if the FDA authorizes use and ACIP votes to recommend the candidate vaccines. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization. The codes and crosswalk for candidate COVID-19 vaccines will be posted for preview in phases as the late-stage clinical trials for candidate vaccines progress.
Note: Codes will become effective only upon EUA issuance or BLA licensure of COVID-19 vaccine(s) by the Food and Drug Administration (FDA) COVID-19 Vaccine Codes Preview Posting of COVID-19 Vaccine Codes and Crosswalk for Currently Authorized Vaccines and Anticipation of Potential Vaccine Availability under Emergency Use Authorization (EUA)
0 kommentar(er)
